-
公开(公告)号:AU8574801A
公开(公告)日:2001-12-24
申请号:AU8574801
申请日:2001-06-15
Applicant: BASF AG
Inventor: GENESTE HERVE , KLING ANDREAS , LANGE UDO , LAUTERBACH ARNULF , SEITZ WERNER , GRAEF CLAUDIA ISABELLA , SUBKOWSKI THOMAS , HORNBERGER WILFRIED
IPC: A61K45/06 , A61P9/00 , C07D223/16 , C07D403/12 , A61K31/55
Abstract: The invention relates to novel compounds which bind to integrin receptors, their use as ligands of integrin receptors, in particular as ligands of the αv&bgr;3 integrin receptor, and pharmaceutical preparations comprising these compounds.
-
公开(公告)号:NO20014961L
公开(公告)日:2001-11-07
申请号:NO20014961
申请日:2001-10-12
Applicant: BASF AG
Inventor: ZECHEL JOHANN-CHRISTIAN , KLING ANDREAS , GENESTE HERVE , LANGE UDO , LAUTERBACH ARNULF , GRAEF CLAUDIA ISABELLA , SUBKOWSKI THOMAS , SADOWSKI JENS , HORNBERGER WILFRIED
IPC: A61K31/505 , C07D239/36 , A61K45/00 , A61K45/06 , A61P3/14 , A61P7/02 , A61P9/10 , A61P9/12 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/08 , A61P19/10 , A61P29/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , C07D239/34 , C07D239/60 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07D233/54
Abstract: The invention relates to novel compounds which bind to integrin receptors, to their preparation, to their use as integrin receptor ligands and for treating diseases, to pharmaceutical preparations comprising these compounds, and to pharmaceutical preparations comprising at least one other active compound.
-
公开(公告)号:NO20014961D0
公开(公告)日:2001-10-12
申请号:NO20014961
申请日:2001-10-12
Applicant: BASF AG
Inventor: ZECHEL JOHANN-CHRISTIAN , KLING ANDREAS , GENESTE HERVE , LANGE UDO , LAUTERBACH ARNULF , GRAEF CLAUDIA ISABELLA , SUBKOWSKI THOMAS , SADOWSKI JENS , HORNBERGER WILFRIED
IPC: A61K31/505 , C07D239/36 , A61K45/00 , A61K45/06 , A61P3/14 , A61P7/02 , A61P9/10 , A61P9/12 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/08 , A61P19/10 , A61P29/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , C07D239/34 , C07D239/60 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07D
Abstract: The invention relates to novel compounds which bind to integrin receptors, to their preparation, to their use as integrin receptor ligands and for treating diseases, to pharmaceutical preparations comprising these compounds, and to pharmaceutical preparations comprising at least one other active compound.
-
公开(公告)号:CA2386230A1
公开(公告)日:2001-04-12
申请号:CA2386230
申请日:2000-10-02
Applicant: BASF AG
Inventor: HORNBERGER WILFRIED , GENESTE HERVE
IPC: A61K38/00 , A61K45/00 , A61K45/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P19/02 , A61P29/00 , A61P37/06 , A61P43/00 , C07D239/34 , C07D263/34 , C07D277/48 , C07D307/68 , C07D333/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07K5/02 , A61K38/19
Abstract: The invention relates to the use of modulators of cytokine mediated signalli ng pathways in combination with integrin .alpha.v.beta.3 receptor antagonists f or the treatment or prevention of diseases, particularly to the use of pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin .alpha.v.beta.3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.
-
公开(公告)号:DE19919218A1
公开(公告)日:2000-11-02
申请号:DE19919218
申请日:1999-04-28
Applicant: BASF AG
Inventor: KLING ANDREAS , LANGE UDO , LAUTERBACH ARNULF , GENESTE HERVE , SUBKOWSKI THOMAS , ZECHEL JOHANN-CHRISTIAN , DAX CLAUDIA ISABELLA
IPC: C07C275/42 , C07D263/34 , C07D277/48 , C07D277/56 , C07D307/68 , C07D333/38 , C07D409/12 , C07D413/12 , C07D417/12 , C07K5/078 , A61K38/05
Abstract: Peptide compounds (I) are new. Peptide derivatives of formula A-E-G-L (I) and their salts, prodrugs, enantiomers, diastereomers and tautomers are new. L = -N(R4)-CHR3-(CHR2)a-T; a = 0 or 1; T = COOH or group hydrolyzable to COOH; R2 = H, NHSO2R21, NHCOR21 or NHCOOR22; R21 = 1-6C alkyl, 3-6C cycloalkyl, (1-4C) alkyl-(3-6C) cycloalkyl, 5-12C bicycloalkyl or 6-18C tricycloalkyl (all optionally substituted (os)); or aryl, aralkyl, alkylheteroaryl or 3-6 membered (un)saturated or aromatic heterocycle (all os by 1-3 groups, two of which may together form a fused (un)saturated or aromatic heterocycle, itself os and optionally carrying a fused os (un)saturated or aromatic ring); R22 = alkyl, aryl, or alkylaryl (all os); R3 = H or -(CH2)b-(X)c-R31; b = 0-3; c = 0 or 1; X = SO2, S, O, CO, NHSO2, OCO, COO, NHCO, CONH, CON(R31), N(R31)CO, SO2NH, SO2N(R31) or N(R31)SO2; R31 = H or OH; 1-6C alkyl, alkoxy, arylalkoxy or aryloxy (all os); primary and optionally secondary or tertiary substituted amino; 2-6C alkenyl or 2-6C alkynyl (both os by 1-4C alkyl or aryl); 5-12C bicycloalkyl or 6-18C tricycloalkyl; or 3-6 membered (un)saturated heterocycle, 3-8C cycloalkyl, aryl or heteroaryl (all os by 1-3 groups, two of which may together form a fused (un)saturated or aromatic carbocycle or heterocycle, itself os and optionally carrying a fused os (un)saturated or aromatic ring); R4 = 1-4C alkyl, 3-6C alkenyl, 3-6C alkynyl or 3-6C cycloalkyl (all os); G = -N(R6)-CH((CH2)dR5)-CO-; d = 0-2;l R5 = as R31; or the side-chain of a natural aminoacid; R6 = H or as R4; E = -(NH)g-(CH2)t-Q-(CH2)e-CO-; e = 0-2; f, g = 0 or 1; Q = os heteroarylene (where two substituents may together form a fused (un)saturated or aromatic carbocycle or heterocycle, itself os and optionally carrying a fused os (un)saturated or aromatic ring); A = R10R11N-C(O)-, R10R11N-C(S)-, R10R11N-C(O)-, R12OC(O)- or R14N-C(=NR13)-; 2-pyridinyl, 2-pyrimidinyl or 4-pyrimidinyl, all substituted by R16 and R17; a diaza-heterocyclic group of formula (A1); a fused imidazole group of formula (A2); 3,4-dihydro-5H-1,3-thiazin-2-yl; uracil-6-yl; 1-aza-cyclopent-1-en-2-yl; 1-aza-cyclohex-1-en-2-yl; 1-aza-cyclohept-1-en-2-yl; or 5-oxo-4,5-dihydro-imidazol-2-yl; R10, R11 = H or -(CH2)h(X)i-R101; or NR10R11 = 3-8 membered os (un)saturated or aromatic heterocycle (optionally containing two further O, N or heteroatoms); h = 0-3; i = 0 or 1; R101 = as R31 but not H; R12 = alkyl, alkylaryl, 3-6C cycloalkyl, (1-4C) alkyl-(3-6C) cycloalkyl or aryl (all os); R13 = H, OH, CN or CONH2; or 1-4C alkyl, 1-4C alkoxy, -OCO-(1-4C) alkyl, alkylaryl, -O-alkylaryl, -OCO-aryl, -OCO-alkylaryl or -OCO-allyl (all os); R14 = H or (all os) 1-4C alkyl, -COO-(1-4C) alkyl, alkylaryl, -COO-alkylaryl, -COO-allyl, -CO-(1-4C) alkyl, -CO-alkylaryl or -CO-allyl; R15 = H or (all os) 1-4C alkyl, aryl or alkylaryl; R16, R17 = NH2, halo or (all os) 1-4C alkyl, 1-4C alkoxy or aryl; V = CH2CH2, CH=CH, 1,2-cyclohexylene, 1,2-cyclohex-1-enylene, (CH2)3 or CH2C(Me)2CH2; Z1-Z4 = CH, C(Me), C(Cl) or N; heterocycles contain 1-3 of O, S and/or N.
-
公开(公告)号:DE50106325D1
公开(公告)日:2005-06-30
申请号:DE50106325
申请日:2001-06-06
Applicant: BASF AG
Inventor: GENESTE HERVE , KLING ANDREAS , LANGE UDO , SEITZ WERNER , GRAEF ISABELLA , SUBKOWSKI THOMAS , HORNBERGER WILFRIED , LAUTERBACH ARNULF
IPC: C07D223/10 , A61K31/55 , A61K31/5513 , A61K45/00 , A61K45/06 , A61P3/10 , A61P5/18 , A61P7/00 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/12 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P29/00 , A61P31/00 , A61P31/12 , A61P33/00 , A61P35/00 , A61P43/00 , C07D263/48 , C07D277/08 , C07D307/68 , C07D333/38 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04 , C07K5/023
Abstract: The invention relates to the use of cyclic compounds as ligands of integrin receptors, in particular as ligands of the alpha V beta 3 integrin receptor, the novel compounds themselves, their use, and pharmaceutical preparations comprising these compounds.
-
公开(公告)号:AR032889A1
公开(公告)日:2003-12-03
申请号:ARP010103835
申请日:2001-08-10
Applicant: BASF AG
Inventor: GENESTE HERVE , KLING ANDREAS , LAUTERBACH ARNULF , GRAEF CLAUDIA ISABELLA , SUBKOWSKI THOMAS , HORNBERGER W
IPC: C07D401/12 , A61K31/55 , A61K45/00 , A61K45/06 , A61P3/10 , A61P3/14 , A61P5/18 , A61P7/02 , A61P7/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P19/10 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P33/00 , A61P35/00 , A61P35/04 , A61P41/00 , A61P43/00 , C07D277/28 , C07D403/12 , C07D471/04 , C07D211/26 , C07D227/04 , C07D247/00 , C07D495/04
Abstract: Un compuesto de diaril azepina representado por la formula B-G-L, donde B, G y L poseen los significados siguientes: L es un elemento estructural de la formula U-T donde T es un grupo COOH, un radical hidrolizable a COOH o un radical bioisoestérico a COOH y ûU- es û(XL)a-CRL1RL2)b-CRL1=CRL2-, etinileno o =CRL1-, en donde a es 0 o 1, b es 0, 1 o 2, XL es CRL3RL4, NRL5, oxígeno o azufre, RL1, RL2, RL3, RL4, independientemente entre sí son hidrogeno, -T, -OH, -NRL6RL7, -CO-NH2, un radical halogeno, un alquilo C1-6 ramificado o lineal, opcionalmente sustituido, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, -CO-NH(alquilo C1-6), -CO-NH (alquilo C1-6)2 o radical alcoxilo C1-4, un radical alquileno C1-2-T opcionalmente sustituido, alquenileno C2-T o alquinileno C2-T, un arilo opcionalmente sustituido o radical arilalquilo o en cada caso independientemente entre sí dos radicales RL1 y RL2 o RL3 y RL4 u opcionalmente RL1 y RL3 son juntos un carbociclo o heterociclo saturado o no saturado opcionalmente sustituido de 3 a 7 miembros que pueden contener hasta 3 heteroátomos diferentes o idénticos de O, N, S, RL5, RL6, RL7, independientemente entre sí son hidrogeno, un alquilo C1-6 ramificado o lineal, opcionalmente sustituido, C3-7 cicloalquilo, CO-O-alquilo C1-6, SO2-alquilo C1-6 o radical CO-alquilo C1-6 o un CO-O-alquilenarilo opcionalmente sustituido, SO2-arilo, CO-arilo, SO2-alquilenoarilo o radical CO-alquilenoarilo, G es un elemento estructural de la formula (1) donde el elemento estructural B está enlazado por medio de Ar y el elemento estructural L que está enlazado mediante XG al elemento estructural G por medio de un unico enlace doble y Ar es un carbociclo o heterociclo de 3 a 10 miembros fusionado, aromático que puede contener hasta 4 heteroátomos idénticos o diferentes, N, S y es opcionalmente sustituido por hasta 4 sustituyentes, DG es un carbociclo o heterociclo de 3 a 10 miembros fusionado, no saturado o aromático opcionalmente sustituido, el cual puede contener hasta 4 heteroátomos diferentes o idénticos O, N, S; XG es CRG1 o nitrogeno, en el caso de un unico enlace al elemento estructural L, o átomo de carbono, en el caso de un enlace doble al elemento estructural L, WG es ûYG-N(RG5)û o -N(RG5)-YG-, YG es CO, C, C=NRG2 o CRG3RG4, RG1 es hidrogeno, halogeno, un grupo hidroxilo o un alquilo C1-6 ramificado o lineal, opcionalmente sustituido o radical alcoxilo C1-4; RG2 es hidrogeno, un grupo hidroxilo, un alquilo C1-6 ramificado o lineal, opcionalmente sustituido, alcoxilo C1-4 cicloalquilo C3-7 o radical ûO-cicloalquilo C3-7 o un arilo opcionalmente sustituido, -O-arilo, arilalquilo o radical ûO-alquilenarilo, RG3, RG4 independientemente entre si son hidrogeno o un alquilo C1-6 ramificado o lineal, opcionalmente sustituido, alquenilo C2-6, alquinilo C2-6 o radical alcoxilo C1-4 o ambos radicales RG3 y RG4 son juntos un acetal cícliclo ûO-CH2-CH2-O- o ûO-CH2-O o ambos radicales RG3 y RG4 son juntos un radical cicloalquilo C3-7 opcionalmente sustituido, con la condicion que como el sustituyente de los radicales alquilo C1-6, se excluyen los grupos COOH y éster de ácido carboxílico, RG5 es un radical RG5A o un radical alquileno C0-6-RG5B, alquenileno C2-4RG5B, alquinileno C2-4-RG5B, oxoalquileno C1-6-RG5B, oxoalquenileno C2-4-RG5B, oxoalquinileno C2-4-RG5B, aminoalquileno-C1-4-RG5B, aminoalquenileno C2-4-RG5B, aminoalquinileno C2-4-RG5B, alquileno C2-4-RG5B, opcionalmente sustituido por uno o más radicales seleccionados del grupo que consiste de: RG5A y RG5C, RG5A es un radical CORG5G, COC(RG5E)2(RG5H), CSRG5G, S(O)g1-ORG5E, S(O)g1-N(RG5E)(RG5F), PO(ORG5E), PO(ORG5E)2, B(ORG5E)2, NO2 o tetrazolilo, RG5B es hidrogeno o un cicloalquilo C3-7 opcionalmente sustituido, cicloheteroalquilo C3-7 arilo o radical hetarilo, RG5C es hidrogeno, halogeno CN, NO2, ORG5D, CF3, o un radical N(RG5E)(RG5D), CF3S(O)g2, CO2RG5E, CO-N(RG5E)2, alquileno C0-6-RG5B, oxoalquileno C1-6-RG5B, alquenileno C2-4-RG5B o alquinileno C2-4-RG5B, RG5D es un radical RG5E, -CO-RG5E, CO-ORG5J, -CO-N(RG5E)2, S(O)g1-RG5E o S(O)g1-N(RG5E)2, RG5E es hidrogeno, un alquilo C1-6 opcionalmente sustituido, aril-alquileno C0-6, cicloalquil C3-7-alquileno C0-6, hetarilo o radical hetarilaquilo, RG5F es un radical RG5E, CO-RG5E o CO-ORG5E, RG5G es un radical ORG5E, N(RG5E)(RG5F), N(RG5E)-SO2-RG5E, N(RG5E)(ORG5E), OûC(RG5E)2-CO-ORG5E, O-C(RG5E)2-O-CO-RG5E, O-C(RG5E)2-CO-N(RG5E)2 o CF3, RG5H es un radical ORG5E, CN, S(O)g2-RG5E, S(O)g1-N(RG5E)2, CO-RG5E, C(O)N(RG5E)2, o CO2-RG5E, RG5J es hidrogeno o un alquilo C1-6 opcionalmente sustituido o radical aril-alquileno C0-6, g1 es 1 o 2 y g2 es 0, 1 o 2, con la condicion que si WG=-YG-N(RG5)- el radical û(CH2)m-CORG6 se excluye para RG5, en donde m es 1 o 2, RG6 es ûOR', -NR'R'', -NR'SO2R''', -NR'OR', -OCR'2C(O)OR', -OCR'2OC(O)R', -OCR'2C(O)NR'2, -CF3 o ûCOC(R')2RG7, RG7 es ûOR', -CN, -S(O)rR', S(O)2N(R')2, -C(O)R'C(O)NR'2 o ûCO2R', r es 0, 1 o 2; R' es hidrogeno, alquilo C1-6, cicloalquil C3-7-alquilo C0-4 o aril-alquilo C0-4, R'' es R', -C(O)R' o ûC(O)ORG8, R''' es alquilo C1-6, cicloalquil C3-7-alquilo C0-4 o aril-alquilo C0-4, RG8 es hidrogeno, alquilo C1-6, cicloalquil C3-7-alquilo C0-4 o aril-alquilo C0-4, B es un elemento estructural que contiene por lo menos un átomo que, bajo condiciones fisiologicas, puede formar los puentes de hidrogeno como un aceptor de hidrogeno, en donde por lo menos un átomo de aceptor de hidrogeno posee una distancia de 4 a 15 uniones de átomo del elemento estructural G a lo largo del posible trayecto más corto en la longitud del esqueleto de elemento estructural, o las sales fisiologicamente tolerables, prodrogas y las formas enatioméricamente puras o diastereoméricamente puras y tautoméricas. Los compuestos de formula (1) son ligando del receptor de integrina av b3.
-
公开(公告)号:PL352777A1
公开(公告)日:2003-09-08
申请号:PL35277700
申请日:2000-04-17
Applicant: BASF AG
Inventor: KLING ANDREAS , LANGE UDO , LAUTERBACH ARNULF , GENESTE HERVE , SUBKOWSKI THOMAS , ZECHEL JOHANN CHRISTIAN , GRAEF CLAUDIA ISABELLA , HORNBERGER WILFRIED
IPC: C12N9/99 , A61K31/27 , A61K31/381 , A61K31/421 , A61K31/426 , A61K31/4406 , A61K31/443 , A61K31/4439 , A61K38/00 , A61K45/00 , A61K45/06 , A61P3/10 , A61P3/14 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/08 , A61P9/10 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P29/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P43/00 , C07C275/42 , C07D207/34 , C07D213/56 , C07D249/14 , C07D263/34 , C07D263/48 , C07D277/20 , C07D277/48 , C07D277/56 , C07D307/68 , C07D333/38 , C07D333/40 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07K5/02 , C07K5/023 , A61K38/04 , A61K31/33
Abstract: The invention relates to new compounds which bind to integrin receptors, as well as to their production, their use as integrin receptor antagonists and for the treatment of diseases, pharmaceutical preparations containing said compounds and pharmaceutical preparations containing at least one other active compound.
-
公开(公告)号:CA2418749A1
公开(公告)日:2003-02-10
申请号:CA2418749
申请日:2001-08-09
Applicant: BASF AG
Inventor: GENESTE HERVE , SCHAFER BERND
IPC: C07C37/00 , C07C37/50 , C07C39/24 , C07C45/00 , C07C45/60 , C07C47/565 , C07C49/825 , C07C51/15 , C07C65/05 , C07D309/12 , C07F5/02 , C07F7/08
Abstract: The invention relates to a method for producing 2- and 2,5-substituted derivatives of 4-(trifluoromethyl)-phenol and 4-(2-trifluoromethyl)-phenyl)- 2- tetrahydropyranyl) ether and to novel derivatives. Said method is characterised in that a compound of formula (2) 4-(trifluoromethylphenyl)-2- (tetrahydropyranyl) ether is reacted with an electrophile E-X or a combinati on of electrophiles E-X and E-Y in the presence of a base, X and Y having the meanings given in the description.
-
公开(公告)号:SK2002002A3
公开(公告)日:2002-11-06
申请号:SK2002002
申请日:2000-08-01
Applicant: BASF AG
Inventor: KLING ANDREAS , GENESTE HERVE , LANGE UDO , LAUTERBACH ARNULF , GRAEF CLAUDIA ISABELLA , SUBKOWSKI THOMAS , HOLZENKAMP UTA , MACK HELMUT , SADOWSKI JENS , HORNBERGER WILFRIED , LAUX VOLKER
IPC: A61K31/4402 , A61K31/55 , A61K31/5513 , A61P3/14 , A61P5/18 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/08 , A61P19/10 , A61P29/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P35/04 , A61P43/00 , C07D213/74 , C07D223/20 , C07D243/38 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/12 , C07D409/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04 , C07D495/14 , C07D213/73 , C07D491/04
Abstract: The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.
-
-
-
-
-
-
-
-
-